Helen Torley Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALOGet Rating) CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 19th. The shares were sold at an average price of $52.41, for a total value of $524,100.00. Following the sale, the chief executive officer now owns 587,177 shares of the company’s stock, valued at approximately $30,773,946.57. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Helen Torley also recently made the following trade(s):

  • On Thursday, December 15th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $57.37, for a total value of $573,700.00.
  • On Thursday, November 17th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $52.15, for a total transaction of $521,500.00.

Halozyme Therapeutics Stock Performance

HALO stock opened at $51.46 on Friday. Halozyme Therapeutics, Inc. has a 1 year low of $31.36 and a 1 year high of $59.46. The stock has a market capitalization of $6.96 billion, a price-to-earnings ratio of 34.54, a PEG ratio of 0.65 and a beta of 1.23. The company has a debt-to-equity ratio of 15.37, a quick ratio of 5.03 and a current ratio of 5.97. The stock’s fifty day moving average is $55.31 and its two-hundred day moving average is $48.30.

Halozyme Therapeutics (NASDAQ:HALOGet Rating) last posted its earnings results on Tuesday, November 8th. The biopharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.21. Halozyme Therapeutics had a net margin of 36.37% and a return on equity of 134.71%. The firm had revenue of $208.98 million during the quarter, compared to analyst estimates of $187.87 million. On average, research analysts predict that Halozyme Therapeutics, Inc. will post 2.07 EPS for the current year.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HALO. Victory Capital Management Inc. boosted its position in Halozyme Therapeutics by 206.7% during the 2nd quarter. Victory Capital Management Inc. now owns 1,790,044 shares of the biopharmaceutical company’s stock worth $78,761,000 after acquiring an additional 1,206,368 shares during the period. Franklin Resources Inc. increased its stake in Halozyme Therapeutics by 1,548.8% during the 2nd quarter. Franklin Resources Inc. now owns 688,216 shares of the biopharmaceutical company’s stock valued at $30,282,000 after buying an additional 646,475 shares during the period. Driehaus Capital Management LLC lifted its stake in shares of Halozyme Therapeutics by 51.9% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,282,492 shares of the biopharmaceutical company’s stock worth $56,430,000 after acquiring an additional 438,429 shares during the period. Bank of Montreal Can boosted its holdings in shares of Halozyme Therapeutics by 1,979.8% in the third quarter. Bank of Montreal Can now owns 431,396 shares of the biopharmaceutical company’s stock valued at $17,450,000 after acquiring an additional 410,654 shares in the last quarter. Finally, Mizuho Markets Americas LLC acquired a new position in shares of Halozyme Therapeutics during the third quarter valued at approximately $14,184,000. 96.32% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on HALO. StockNews.com assumed coverage on shares of Halozyme Therapeutics in a research note on Wednesday, October 12th. They issued a “hold” rating on the stock. SVB Leerink reduced their target price on Halozyme Therapeutics from $62.00 to $61.00 and set an “outperform” rating on the stock in a report on Wednesday, January 11th. Morgan Stanley boosted their price target on Halozyme Therapeutics from $53.00 to $65.00 and gave the company an “overweight” rating in a report on Wednesday, December 21st. JPMorgan Chase & Co. raised their price objective on Halozyme Therapeutics from $53.00 to $54.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 22nd. Finally, Wells Fargo & Company began coverage on shares of Halozyme Therapeutics in a research note on Monday, November 28th. They set an “overweight” rating and a $65.00 target price for the company. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $59.63.

Halozyme Therapeutics Company Profile

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Recommended Stories

Insider Buying and Selling by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.